Unknown

Dataset Information

0

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression.


ABSTRACT:

Background

Medulloblastoma (MB) is the most common pediatric brain tumor. Although standard-of-care treatment generally results in good prognosis, many patients exhibit treatment-associated lifelong disabilities. This outcome could be improved by employing therapies targeting the molecular drivers of this cancer. Attempts to do so in the SONIC HEDGEHOG MB subgroup (SHH-MB) have largely focused on the SHH pathway's principal activator, smoothened (SMO). While inhibitors targeting SMO have shown clinical efficacy, recurrence and resistance are frequently noted, likely resulting from mutations in or downstream of SMO. Therefore, identification of novel SHH regulators that act on the pathway's terminal effectors could be used to overcome or prevent such recurrence. We hypothesized that protein arginine methyltransferase 5 (PRMT5) is one such regulator and investigated its role and potential targeting in SHH-MB.

Methods

PRMT5 expression in SHH-MB was first evaluated. Knockdown and pharmacological inhibitors of PRMT5 were used in SHH-MB sphere cultures to determine its effect on viability and SHH signaling. GLI1 arginine methylation was then characterized in primary SHH-MB tissue using LC-MS/MS. Finally, PRMT5 inhibitor efficacy was evaluated in vivo.

Results

PRMT5 is overexpressed in SHH-MB tissue. Furthermore, SHH-MB viability and SHH activity is dependent on PRMT5. We found that GLI1 isolated from SHH-MB tissues is highly methylated, including three PRMT5 sites that affect SHH-MB cell viability. Importantly, tumor growth is decreased and survival increased in mice given PRMT5 inhibitor.

Conclusions

PRMT5 is a requisite driver of SHH-MB that regulates tumor progression. A clinically relevant PRMT5 inhibitor represents a promising candidate drug for SHH-MB therapy.

SUBMITTER: Wynn DT 

PROVIDER: S-EPMC9586216 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression.

Wynn Daniel T DT   Rodriguez-Blanco Jezabel J   Long Jun J   Yang Fan F   Shen Chen C   Fei Dennis D   Tang Hsin-Yao HY   Hanson Derek D   Robbins David J DJ  

Neuro-oncology advances 20220101 1


<h4>Background</h4>Medulloblastoma (MB) is the most common pediatric brain tumor. Although standard-of-care treatment generally results in good prognosis, many patients exhibit treatment-associated lifelong disabilities. This outcome could be improved by employing therapies targeting the molecular drivers of this cancer. Attempts to do so in the SONIC HEDGEHOG MB subgroup (SHH-MB) have largely focused on the SHH pathway's principal activator, smoothened (SMO). While inhibitors targeting SMO have  ...[more]

Similar Datasets

| S-EPMC3830749 | biostudies-literature
| S-EPMC5680121 | biostudies-literature
| S-EPMC6836472 | biostudies-literature
2024-03-23 | GSE103824 | GEO
| S-EPMC5729635 | biostudies-literature
| S-EPMC10450591 | biostudies-literature
| S-EPMC11750132 | biostudies-literature
| S-EPMC9867863 | biostudies-literature
| S-EPMC4386991 | biostudies-literature
| S-EPMC2853117 | biostudies-literature